Personal history of autoimmune diseases and risk of MM and MGUS
Category or condition . | MM . | MGUS . | ||||
---|---|---|---|---|---|---|
MM patients (n = 19 112) . | Controls (n = 75 408) . | OR* (95% CI) [P] . | MGUS patients (n = 5403) . | Controls (n = 21 209) . | OR* (95% CI) [P] . | |
Total autoimmune disease† | 443 | 1683 | 1.0 (0.9-1.2) | 383 | 741 | 2.1 (1.9-2.4) |
Autoantibodies detectable | 277 | 1210 | 0.9 (0.8-1.02) | 246 | 472 | 2.1 (1.8-2.5) |
Systemic involvement | 148 | 685 | 0.9 (0.7-1.01) | 162 | 272 | 2.4 (2.0-2.9) |
Rheumatoid arthritis | 111 | 567 | 0.8 (0.6-0.9) | 122 | 224 | 2.2 (1.7-2.7) |
Systemic sclerosis | 7 | 40 | 0.7 (0.3-1.5) | 7 | 4 | 6.9 (2.0-23.6) |
Sjögren syndrome | 4 | 17 | 0.9 (0.3-2.7) | 15 | 13 | 4.5 (2.2-9.6) |
Systemic lupus erythematosus | 11 | 29 | 1.5 (0.7-3.0) | 7 | 12 | 2.3 (0.9-5.9) |
Polymyositis or dermatomyositis | 4 | 11 | 1.4 (0.5-4.5) | 3 | 5 | 2.3 (0.6-9.8) |
Organ involvement | 137 | 559 | 1.0 (0.8-1.2) | 93 | 218 | 1.7 (1.3-2.2) |
Hashimoto thyroiditis | 5 | 16 | 1.2 (0.4-3.4) | 3 | 2 | 5.9 (0.99-35.5) |
Graves disease | 9 | 52 | 0.7 (0.3-1.4) | 4 | 23 | 0.7 (0.2-2.0) |
Addison disease | 4 | 17 | 0.9 (0.3-2.7) | 3 | 17 | 0.7 (0.2-2.4) |
Pernicious anemia | 48 | 156 | 1.2 (0.9-1.7) | 19 | 41 | 1.8 (1.1-3.1) |
Autoimmune hemolytic anemia | 4 | 1 | 15.8 (1.8-141.0) | 6 | 0 | ∞ [< .05] |
Immune thrombocytopenia | 4 | 10 | 1.6 (0.5-5.0) | 7 | 4 | 6.9 (2.0-23.7) |
Primary biliary cirrhosis | 1 | 14 | 0.3 (0.0-2.1) | 3 | 4 | 3.0 (0.7-13.2) |
Discoid lupus erythematosus | 3 | 6 | 2.0 (0.5-7.9) | 2 | 7 | 1.1 (0.2-5.4) |
Myasthenia gravis | 4 | 16 | 1.0 (0.3-2.9) | 1 | 6 | 0.6 (0.1-5.4) |
Polyarteritis nodosa | 1 | 3 | 1.3 (0.1-12.7) | 4 | 0 | ∞ [< .05] |
Guillain-Barré syndrome | 2 | 15 | 0.5 (0.1-2.3) | 6 | 8 | 3.0 (1.03-8.5) |
Diabetes type 1 | 0 | 1 | 0 [1.00] | 0 | 5 | 0 [.59] |
Celiac disease | 6 | 12 | 2.0 (0.7-5.3) | 6 | 8 | 3.0 (1.03-8.6) |
Dressler syndrome | 2 | 13 | 0.6 (0.1-2.7) | 3 | 9 | 1.3 (0.4-4.8) |
Chronic rheumatic heart disease | 30 | 159 | 0.7 (0.5-1.1) | 21 | 48 | 1.7 (1.03-2.9) |
Multiple sclerosis | 14 | 64 | 0.9 (0.5-1.5) | 6 | 32 | 0.7 (0.3-1.8) |
Amyotrophic lateral sclerosis | 1 | 6 | 0.7 (0.1-5.4) | 2 | 2 | 3.9 (0.6-27.8) |
Autoantibodies not detectable | 189 | 538 | 1.4 (1.2-1.6) | 171 | 314 | 2.2 (1.8-2.6) |
Rheumatic fever | 9 | 20 | 1.8 (0.8-3.9) | 7 | 12 | 2.3 (0.9-5.9) |
Sarcoidosis | 15 | 67 | 0.9 (0.5-1.5) | 16 | 37 | 1.7 (0.95-3.1) |
Reiter disease | 1 | 2 | 2.0 (0.2-21.8) | 1 | 5 | 0.8 (0.1-6.8) |
Crohn disease | 16 | 60 | 1.1 (0.6-1.8) | 15 | 46 | 1.3 (0.7-2.3) |
Ulcerative colitis | 33 | 97 | 1.3 (0.9-2.0) | 20 | 58 | 1.4 (0.8-2.3) |
Ankylosing spondylitis | 12 | 40 | 1.2 (0.6-2.3) | 15 | 22 | 2.7 (1.4-5.2) |
Polymyalgia rheumatica | 56 | 116 | 1.9 (1.4-2.6) | 58 | 79 | 2.9 (2.1-4.1) |
Psoriasis | 33 | 130 | 1.0 (0.7-1.5) | 24 | 62 | 1.5 (0.95-2.4) |
Giant cell arteritis | 16 | 8 | 7.8 (3.3-18.2) | 20 | 7 | 11.3 (4.8-26.7) |
Aplastic anemia | 9 | 16 | 2.2 (0.98-5.0) | 7 | 1 | 27.4 (3.4-222.4) |
Category or condition . | MM . | MGUS . | ||||
---|---|---|---|---|---|---|
MM patients (n = 19 112) . | Controls (n = 75 408) . | OR* (95% CI) [P] . | MGUS patients (n = 5403) . | Controls (n = 21 209) . | OR* (95% CI) [P] . | |
Total autoimmune disease† | 443 | 1683 | 1.0 (0.9-1.2) | 383 | 741 | 2.1 (1.9-2.4) |
Autoantibodies detectable | 277 | 1210 | 0.9 (0.8-1.02) | 246 | 472 | 2.1 (1.8-2.5) |
Systemic involvement | 148 | 685 | 0.9 (0.7-1.01) | 162 | 272 | 2.4 (2.0-2.9) |
Rheumatoid arthritis | 111 | 567 | 0.8 (0.6-0.9) | 122 | 224 | 2.2 (1.7-2.7) |
Systemic sclerosis | 7 | 40 | 0.7 (0.3-1.5) | 7 | 4 | 6.9 (2.0-23.6) |
Sjögren syndrome | 4 | 17 | 0.9 (0.3-2.7) | 15 | 13 | 4.5 (2.2-9.6) |
Systemic lupus erythematosus | 11 | 29 | 1.5 (0.7-3.0) | 7 | 12 | 2.3 (0.9-5.9) |
Polymyositis or dermatomyositis | 4 | 11 | 1.4 (0.5-4.5) | 3 | 5 | 2.3 (0.6-9.8) |
Organ involvement | 137 | 559 | 1.0 (0.8-1.2) | 93 | 218 | 1.7 (1.3-2.2) |
Hashimoto thyroiditis | 5 | 16 | 1.2 (0.4-3.4) | 3 | 2 | 5.9 (0.99-35.5) |
Graves disease | 9 | 52 | 0.7 (0.3-1.4) | 4 | 23 | 0.7 (0.2-2.0) |
Addison disease | 4 | 17 | 0.9 (0.3-2.7) | 3 | 17 | 0.7 (0.2-2.4) |
Pernicious anemia | 48 | 156 | 1.2 (0.9-1.7) | 19 | 41 | 1.8 (1.1-3.1) |
Autoimmune hemolytic anemia | 4 | 1 | 15.8 (1.8-141.0) | 6 | 0 | ∞ [< .05] |
Immune thrombocytopenia | 4 | 10 | 1.6 (0.5-5.0) | 7 | 4 | 6.9 (2.0-23.7) |
Primary biliary cirrhosis | 1 | 14 | 0.3 (0.0-2.1) | 3 | 4 | 3.0 (0.7-13.2) |
Discoid lupus erythematosus | 3 | 6 | 2.0 (0.5-7.9) | 2 | 7 | 1.1 (0.2-5.4) |
Myasthenia gravis | 4 | 16 | 1.0 (0.3-2.9) | 1 | 6 | 0.6 (0.1-5.4) |
Polyarteritis nodosa | 1 | 3 | 1.3 (0.1-12.7) | 4 | 0 | ∞ [< .05] |
Guillain-Barré syndrome | 2 | 15 | 0.5 (0.1-2.3) | 6 | 8 | 3.0 (1.03-8.5) |
Diabetes type 1 | 0 | 1 | 0 [1.00] | 0 | 5 | 0 [.59] |
Celiac disease | 6 | 12 | 2.0 (0.7-5.3) | 6 | 8 | 3.0 (1.03-8.6) |
Dressler syndrome | 2 | 13 | 0.6 (0.1-2.7) | 3 | 9 | 1.3 (0.4-4.8) |
Chronic rheumatic heart disease | 30 | 159 | 0.7 (0.5-1.1) | 21 | 48 | 1.7 (1.03-2.9) |
Multiple sclerosis | 14 | 64 | 0.9 (0.5-1.5) | 6 | 32 | 0.7 (0.3-1.8) |
Amyotrophic lateral sclerosis | 1 | 6 | 0.7 (0.1-5.4) | 2 | 2 | 3.9 (0.6-27.8) |
Autoantibodies not detectable | 189 | 538 | 1.4 (1.2-1.6) | 171 | 314 | 2.2 (1.8-2.6) |
Rheumatic fever | 9 | 20 | 1.8 (0.8-3.9) | 7 | 12 | 2.3 (0.9-5.9) |
Sarcoidosis | 15 | 67 | 0.9 (0.5-1.5) | 16 | 37 | 1.7 (0.95-3.1) |
Reiter disease | 1 | 2 | 2.0 (0.2-21.8) | 1 | 5 | 0.8 (0.1-6.8) |
Crohn disease | 16 | 60 | 1.1 (0.6-1.8) | 15 | 46 | 1.3 (0.7-2.3) |
Ulcerative colitis | 33 | 97 | 1.3 (0.9-2.0) | 20 | 58 | 1.4 (0.8-2.3) |
Ankylosing spondylitis | 12 | 40 | 1.2 (0.6-2.3) | 15 | 22 | 2.7 (1.4-5.2) |
Polymyalgia rheumatica | 56 | 116 | 1.9 (1.4-2.6) | 58 | 79 | 2.9 (2.1-4.1) |
Psoriasis | 33 | 130 | 1.0 (0.7-1.5) | 24 | 62 | 1.5 (0.95-2.4) |
Giant cell arteritis | 16 | 8 | 7.8 (3.3-18.2) | 20 | 7 | 11.3 (4.8-26.7) |
Aplastic anemia | 9 | 16 | 2.2 (0.98-5.0) | 7 | 1 | 27.4 (3.4-222.4) |